semaxanib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702577
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
semaxanib-resistant FLT3 mutants
Click the image above or here to open this pathway in the Pathway Browser
Semaxanib, also known as SU5614, is an investigational type I tyrosine kinase inhibitor with activity against a wide range of receptor tyrosine kinases. It is not currently approved for clinical use. This pathway describes FLT3 mutants that show resistance to semaxanib-mediated inhibition (Yee et al, 2002; Spiekermann et al, 2003).
Literature References
PubMed ID Title Journal Year
12406902 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3

Schnittger, S, Dirschinger, RJ, Schwab, R, Buske, C, Gilliland, DG, Kelly, LM, Faber, F, Spiekermann, K, Bagrintseva, K, Hiddemann, W

Blood 2003
12351406 SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Heinrich, MC, O'Farrell, AM, Wait, CL, Yee, KW, Griffith, DJ, McGreevey, LS, Smolich, BD, McMahon, G, Cherrington, JM

Blood 2002
Participants
Events
Participates
as an event of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!